Shanghai Kaibao Pharmaceutical Co., Ltd.

Shanghai Kaibao Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise listed on the ChiNext board of the Shenzhen Stock Exchange since 2010. The company specializes in the research, development, manufacture, and sale of modern Chinese medicine. It is recognized as a national high-tech industrialization demonstration project base for Chinese medicine and is among the top 100 pharmaceutical enterprises in China. The company is notable for being one of the first to receive approval for new GMP (2010 edition) injections. The company's main product, Tanreqing injection, is an exclusive patented product classified as a national second-class new traditional Chinese medicine, known for its significant curative effects and low side effects. In addition to Tanreqing, Shanghai Kaibao has developed various other clinical products, including Youxinding capsule and a range of antitumor medications. The company operates several wholly-owned subsidiaries focused on different aspects of pharmaceutical development, including traditional Chinese medicine, health technology, and investment management, enhancing its competitiveness and market presence in the pharmaceutical industry.

The company has built a high-tech platform with strong R&D and production capability transformation, and also Shanghai academician expert workstation with many research projects. At present, At present, the main product has a definite clinical curative effect and stable quality, and the market coverage rate and enterprise recognition are gradually improved lead to a gradually improved market fraction of coverage and enterprise recognition. Jointly cooperation with Shanghai Institute and Chongqing University study 689 material basic research and improve the quality standard to reach a result 8893 which lay a solid foundation to ensure the product quality. In collaboration with China Medicine University work out the research of pharmacokinetics to provide a scientific basis for clinical use. Finished the national administration of traditional Chinese medicine project 30 thousand cases safety evaluation through real world safety analysis. Working with China Song Ching Ling foundation to carry out the 10 thousand cases of reevaluation about project effectiveness on the research of senile chronic obstructive pulmonary disease. Undertake the National Development and Reform Commission project of the standardization construction of Tanreqing Injection to build the product into an exemplary brand of the industry. Cooperate with China Academy of Chinese Academy of Sciences in the study of drug-resistant to make positive contributions to solve the world drug resistance problem. Company focuses on sales team building and marketing mode improvement to insist on academic promotion also think highly of terminal market maintenance and development to improve the market share and brand competitiveness.